Discover trends, market shifts, and competitive outlooks for the major depressive disorder industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has The Major Depressive Disorder Market Growth Evolved From 2024 To 2025, And What’s Ahead?

Over the years, the market size for major depressive disorder has experienced a consistent growth. It is set to expand from a value of $6.12 billion in 2024 to reach $6.28 billion by 2025, showcasing a compound annual growth rate (CAGR) of 2.6%. The significant rise during the historical period is the result of advancements in pharmaceuticals, heightened mental health consciousness, the provision of psychological therapies, and diverse public health campaigns.

In the coming years, the market size for major depressive disorder is projected to experience consistent growth, ultimately reaching $7.13 billion in 2029 with a compound annual growth rate (CAGR) of 3.2%. This predicted growth during the forecast period can be credited to the advancements in precision medicine, the emergence of telepsychiatry and teletherapy, new treatment methods, as well as the worldwide expansion of mental health services. Key trends during the forecast period likely to influence the market are early intervention, peer assistance and online gatherings, holistic methodologies, and resilience and coping tactics.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13042&type=smp

What External and Internal Drivers Are Contributing to the Growth of the Major Depressive Disorder Market?

The increasing prevalence of substance and alcohol misuse is expected to boost the development of the major depressive disorder market. Substance and alcohol misuse is marked by hazardous overconsumption of substances, including alcohol, leading to adverse physical, psychological, and societal impacts. This behavior often coincides with major depressive disorder, with both conditions escalating one’s risk of mental and physical harms. In a 2024 report by the Substance Abuse and Mental Health Services Administration, a US health and human services department, data showed that 3.1% of the population (8.9 million people) abused opioids in 2023, while 21.8% of individuals over 12 consumed marijuana, the most commonly misused drug. Furthermore, there was an increase in nicotine vaping among those 12 or older from 8.3% in 2022 to 9.4% in 2024. Consequently, these increasing levels of substance and alcohol misuse are fueling the expansion of the major depressive disorder market. In another driver, the rise in anxiety cases is also expected to contribute to the growth of the major depressive disorder market. Anxiety, a normal reaction to stress, elicits feelings of fear, apprehension, and discomfort. This temporary state of severe and constant worry about everyday situations has a significant effect on major depressive disorders, leading to nervousness, irritability, and issues with sleep and concentration. Evidence from the American Psychiatric Association, a non-profit organization based in the US, indicated that in 2024, 43% of adults reported more anxiety than the previous year, an increase from 37% in 2023 and 32% in 2022. This rise in anxiety cases is thus propelling the growth of the major depressive disorder market.

What Segment Types Define the Major Depressive Disorder Market Structure?

The major depressive disorder market covered in this report is segmented –

1) By Treatment: Psychotherapy, Medications, Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Other Treatments

2) By Diagnosis: Physical Examinations, Laboratory Tests, Psychiatric Evaluations, Diagnostic And Statistical Manual of Mental Disorders (DSM-5), Other Diagnosis

3) By End-User: Clinics, Hospitals, Other End-Users

Subsegments:

1) By Psychotherapy: Cognitive Behavioral Therapy (CBT), Interpersonal Therapy (IPT), Dialectical Behavior Therapy (DBT), Psychodynamic Therapy

2) By Medications: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Atypical Antidepressants

3) Electroconvulsive Therapy (ECT): Unilateral ECT, Bilateral ECT, Modified ECT

4) Transcranial Magnetic Stimulation (TMS): Repetitive Transcranial Magnetic Stimulation (rTMS), Deep Transcranial Magnetic Stimulation (dTMS), Theta Burst Stimulation (TBS), Navigated Brain Stimulation (nTMS)

5) Other: Cognitive Behavioral Therapy (CBT), Psychodynamic Therapy, Interpersonal Therapy (IPT), Vagus Nerve Stimulation (VNS), Ketamine Therapy, Bright Light Therapy, Psychedelic-Assisted Therapy, Medication (Antidepressants)

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13042&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Major Depressive Disorder Market?

North America was the largest region in the major depressive disorder market in 2024. The regions covered in major depressive disorder market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Long-Term Trends Are Transforming the Competitive Landscape of the Major Depressive Disorder Market?

Leading enterprises in the major depressive disorder market are concentrating on creating innovative products and securing their approval to gain a competitive edge. The approval rate of drugs for treating major depressive disorder, such as VRAYLAR (cariprazine), is on a rise due to the increasing need for safer and more effective treatment options. For example, in December 2022, the US-based pharmaceutical company AbbVie Inc., received an approval for VRAYLAR (cariprazine) as a supplemental treatment to antidepressants for adult patients of major depressive disorder (MDD), granted by Food and Drug Administration (FDA), a U.S. federal agency. VRAYLAR, an innovative atypical antipsychotic medication, helps in maintaining a balance between dopamine and serotonin levels in the brain. It’s the first of its kind to be approved as a supplemental treatment for major depressive disorder. Additionally, it comes in the form of a capsule and is taken once a day.

View the full report here:

https://www.thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report

What Is the Definition of the Major Depressive Disorder Market?

Major depressive disorder refers to a mood disorder or depression that causes a persistent feeling of sadness and loss of interest, which can interfere with daily activities such as sleeping, eating, or working. It goes beyond normal fluctuations in mood and can significantly impact a person’s thoughts, feelings, behavior and physical well-being. The treatment for major depressive disorder involves several medical interventions that support the emotional well-being of an individual.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13042

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model